DCM in Dobermans
Dilated Cardiomyopathy (DCM) is a disease of heart muscle that results in a decreased ability of the heart to pump blood. The prognosis for DCM is often poor, with a less than 50% survival rate one year after clinical signs develop, unless a reversible underlying cause is identified. There is no available cure for Dilated Cardiomyopathy, current techniques focus on extending survival time as long as possible. However the focus of this clinical trial is to evaluate a potential curative treatment for cardiomyopathy in the Doberman Pinscher.
About Dilated Cardiomyopathy
Background
Dilated cardiomyopathy (DCM) is a very common form of heart disease in dogs. Only degenerative valve disease (also called mitral valve disease or endocardiosis or mitral insufficiency) and in some places heartworm disease are more common. It was not until the 1970s, when echocardiography began to be performed in veterinary institutions, that dilated cardiomyopathy could be diagnosed non-invasively with any certain degree of accuracy. The reported prevalence in dogs is approximately 0.5%.
Based upon a national database of dogs presented to veterinary schools in North America, we know that 5.8% of the Doberman Pinschers that were seen at a school had DCM, 5.6% of the Irish Wolfhounds presented had DCM. 3.9% of the Great Danes, 3.4 percent of the Boxers and 2.6% of the St. Bernards. In general, the dogs are middle age (4-10 years of age) with Males being over-represented (2:1). 70-80% of the Dobermans with congestive heart failure due to DCM are male and in a recent paper describing the disease in Dalmatians, all of the affected animals were male. This does not mean that female dogs are not affected by DCM, on the contrary, Dr. O’Grady at the University of Guelph found no sex predilection for Dobermans with subclinical (Asymptomatic or occult) DCM.
Causes
Familial and Genetic Influences
The general feeling is that most cases of DCM have a familial or genetic basis. This is based upon the observation of a higher prevalence in purebred dogs, in certain breeds and within certain families.
There are also strong indications in other breeds such as the Doberman, where DCM can affect more than 50 percent of family members. In Portuguese Water Dogs DCM appears to be autosomal recessive and in English Cocker Spaniels it is associated with a particular immune deficit. An autosomal dominant mode of transmission has been proposed for the Newfoundlands with DCM.
Nutritional Influences
Taurine In the late 1980s taurine deficiency was recognized as the cause of dilated cardiomyopathy in the majority of cats with DCM. Since then investigators in the field have found a relationship between taurine deficiency and DCM in certain breeds such as Cocker Spaniels, Golden Retrievers and Newfoundlands.
Prognosis
Dogs with preclinical disease may go several years without clinical signs, so the diagnosis does not imply immediate risk of morbidity or mortality. Once the dogs become symptomatic, standard therapies for treatment of the heart failure and/or cardiac arrhythmias should be instituted. Nonetheless, the prognosis for Dobermans with DCM is poor.
Unless a reversible underlying cause is identified (e.g. taurine deficiency, primary tachyarrhythmia), the prognosis for DCM is often poor once overt clinical disease (CHF) develops, with most survival times being in months. The median survival time in a large retrospective study with mostly clinically significant dogs was 19 weeks, with one-year and two-year survival rates of 28% and 14%, respectively. In the Doberman, one-year survival rates of 10% or less have been reported, and treatment with triple therapy yielded a median survival time of 130 days.
Treatment
Treatment of dilated cardiomyopathy is quite variable and depends upon the severity of the problem as well as the predominating symptom (e.g. fainting vs. coughing). The treatment may include things such as a moderately sodium restricted diet, diuretics, cardiac glycosides, nitrates, ACE inhibitors and various antiarrhythmic agents. Taurine and carnitine may also be added.
Eligibility
- A diagnosis of DCM and previous evidence of congestive heart failure which has been controlled with medical management.
- A circulating neutralizing antibody titer to the virus vector of less than 1:20
- Owner agreement to authorize participation with informed consent and collection of the heart following euthanasia or death from any cause.
Your dog has no other heart conditions
- Clear of extra-cardiac disease, congenital heart disease or primary mitral valvular disease
Compensation
Free Participation
Enrolled pets receive free:
- Free participation
- bloodwork
- ECHO
- ECG
- Repeated vet checkups
Procedures covered by the study include bloodwork, ECH, and ECG. Enrolled patients also receive repeat screenings at no cost. The value of the study procedure is estimated at $5,000. The cardiology exam ($200) is NOT covered by the study, nor is the cost of thoracic radiographs if not provided by referring veterinarian.
Treatment
- 12 month study
- 5 clinic visits
- 1 gene therapy session
At enrollment, an antibody titer, hematology and biochemistry panel will be used for screening purposes. Dogs will undergo a 3-minute electrocardiogram (ECG), a complete echocardiogram (ECHO) and the owners will complete a quality of life questionnaire. In order to participate in the study, dogs fulfilling the requirements will be randomly assigned to one of two groups: the placebo arm (cardiac injection with saline) or the gene therapy group (cardiac injection with the virus vector: AAV2/6-ARC-s100a1). Standard medical management for DCM and congestive heart failure will continue throughout the study in all dogs. Saline instead of empty virus will be used as the placebo so that control dogs can undergo gene delivery if the treatment group demonstrates a significant improvement compared to the placebo group. Owners will need to commit to re-evaluations at 2, 4, 6, 9, and 12 months at the University of Florida following therapy.
Location
1. Department of Small Animal Clinical Sciences, University of Florida
2015 SW 16th Ave, Gainesville, FL 32608
352-392-2235
Study Team
Cameron Archuleta

Allison O'Kell
DVM, MS, DACVIM
Dr. O’Kell graduated from the Western College of Veterinary Medicine in Saskatoon, Saskatchewan, Canada in 2008. Between 2009 and 2012, she complete a small animal rotating internship followed by a residency in Small Animal Internal Medicine in Blacksburg, Virginia at Virginia Tech. She also completed a Master’s degree in Veterinary and Biomedical Sciences during the residency period. In 2012, Dr. O’Kell became board certified as a diplomate in Small Animal Internal Medicine through the American College of Veterinary Internal Medicine. Dr. O’Kell worked as a clinician in both private specialty practice and academic medicine following her residency. She is currently a Clinical Assistant Professor at the University of Florida in Gainesville. Her research is focused on canine diabetes pathogenesis, with the goal of finding better ways to treat and prevent the disease. She also collaborates with the University of Florida Diabetes Institute to study parallels between diabetes in dogs and people.
Dr. O’Kell has been the primary author on numerous published scientific papers in peer-reviewed journals. She is also a reviewer for several journals and is Associate Editor for the journal Topics in Companion Animal Medicine.

Meg Sleeper
VMD, DACVIM (Cardiology)
Meg Sleeper VMD graduated from the University of Pennsylvania veterinary school cum laude in 1993. Since completing her residency in 1997 and becoming board certified, she has worked in the section of cardiology at Penn with the exception of 1 year in private practice. She is an associate professor of cardiology and was section chief from 2001 through 2011. Primary research interests include inherited heart diseases, in particular inherited cardiomyopathies and therapeutic gene transfer.
Dr. Meg Sleeper has published numerous papers including over 70 peer reviewed original papers, over 50 review papers or case reports, and 4 books. In addition to lecturing at conferences including the American Heart Association, the American College of Veterinary Internal Medicine Forum, the Keystone Veterinary Conference, the World Feline conference and the American Veterinary Medical Association (AVMA), she has been the coordinator for the small animal cardiology section at the AVMA conference since 2009. In 2015 she joined the faculty at the University of Florida veterinary school.
Dr. Sleeper is on the editorial or review board of 11 journals and has served on the research (2008-2011) and examination (2005-2008) committees for the American College of Veterinary Internal Medicine (Cardiology). In early 2011, she was appointed to the Great Ape Heart Project. This project is focused on improving cardiac health in the 4 ape species (Chimpanzees, Gorillas, Bonobos and Orangutans).
